BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bio-Rad Laboratories, Inc. (BIO) Introduces ReadiLink Antibody Labeling Kits


2/28/2014 11:38:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Hercules, CA — February 27, 2014 — Bio-Rad Laboratories, Inc. today announced the launch of its ReadiLink antibody labeling kits, one of the market’s simplest antibody conjugation solution for labeling microscale amounts (50–100 µg) of antibody. These kits are ideal for researchers interested in labeling their own antibodies for flow cytometry and cell sorting applications.

Using the ReadiLink antibody labeling kits, researchers can label their antibodies in two easy steps. The protocol takes only 70 minutes, and the labels are as bright and photostable as traditional dyes. Bio-Rad offers 10 different fluorophores whose excitation/emission wavelengths range from UV to infrared.

“The labeling kits will benefit a wide range of researchers,” said Mary Ferrero, Bio-Rad Product Manager in the Gene Expression Division, Life Sciences Group. “ReadiLink antibody labeling kits are ideal for researchers who are using a rare antibody, are interested in an antibody that is not commercially available with the appropriate fluorophore, or who want to label an antibody with a fluorophore that will fit into their multicolor flow cytometric experiment.”

Bio-Rad also offers additional reagents and consumables for each step of flow cytometry experiments, such as the ReadiDrop™ cell viability assays and primary antibodies.

For more information about Bio-Rad’s antibody labeling kits, please visit www.bio-rad.com/antibodylabeling.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,700 people worldwide and had revenues exceeding $2 billion in 2012. For more information, visit our website at www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Steve Kulisch
Bio-Rad Laboratories, Inc.
510-741-5638
Steve_Kulisch@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES